The Efficacy and Safety of Antinib Hydrochloride Combined With Sindilumab in Advanced NSCLC Patients
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
The combination of immunocheckpoint inhibitors and anti-angiogenesis therapy has synergistic
anti-tumor effect and is a reasonable method to improve the prognosis of patients. Therefore,
in this study, it is hoped that antinib hydrochloride combined with Sinidilizumab can
overcome immunotherapy resistance, improve the efficacy of immunotherapy, and further improve
the survival of patients, so as to provide more clinical evidence for the treatment of
advanced NSCLC patients with negative driver gene after first-line treatment with anti-PD-1
antibody.
Phase:
Phase 2
Details
Lead Sponsor:
Zhejiang Cancer Hospital
Collaborators:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Innovent Biologics (Suzhou) Co. Ltd.